Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases

The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD assoc...

Descripción completa

Detalles Bibliográficos
Autores: Pulito-Cueto, V., Genre, F., López-Mejías, R., Mora-Cuesta, V.M., Iturbe-Fernández, D., Portilla, V., Sebastián Mora-Gil, M., Ocejo-Vinyals, J.G., Gualillo, Oreste, Blanco, R., Corrales, A., Ferraz-Amaro, I., Castañeda, S., Cifrián Martínez, J.M., Atienza-Mateo, B., Remuzgo-Martínez, S., González-Gay Mantecón, Miguel Ángel
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21440
Acceso en línea:https://portalcientifico.sergas.gal//documentos/63f1b8d172e8fb4b23a74790
http://hdl.handle.net/20.500.11940/21440
Access Level:acceso abierto
Palabra clave:Humans
Endothelin-1
Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis
Autoimmune Diseases
Arthritis, Rheumatoid
Biomarkers
AS Santiago
CHUS
Descripción
Sumario:The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD associated with autoimmune diseases (AD-ILD), using a large and well-defined cohort of patients with ILD. A total of 112 patients with IPF, 91 patients with AD-ILD (28 rheumatoid arthritis (RA), 26 systemic sclerosis, 20 idiopathic inflammatory myositis and 17 interstitial pneumonia with autoimmune features) and 44 healthy controls were included. ET-1 serum levels were determined by enzyme-linked immunosorbent assay. A significant increase in ET-1 levels was found in patients with IPF compared to controls. Likewise, AD-ILD patients also showed higher ET-1 levels than controls when the whole cohort was stratified by the type of AD. Similar ET-1 levels were found in IPF and AD-ILD patients, regardless of the underlying AD. Interestingly, increased ET-1 levels were correlated with worse lung function in IPF and RA-ILD patients. Our study supports that serum ET-1 may be useful as a biomarker of ILD, although it could not help in the differential diagnosis between IPF and AD-ILD. Moreover, ET-1 levels may be associated with ILD severity.

Similares en LA Referencia